# Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

> **NCT03976323** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1003 (actual)

## Conditions studied

- Carcinoma, Nonsquamous Non-small-cell Lung

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03976323
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-28
- **Primary completion:** 2024-02-07
- **Final completion:** 2026-01-29
- **Target enrollment:** 1003 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976323, "Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03976323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*